CN101700256A - 用于降低血脂的药物组合物 - Google Patents
用于降低血脂的药物组合物 Download PDFInfo
- Publication number
- CN101700256A CN101700256A CN200910079700A CN200910079700A CN101700256A CN 101700256 A CN101700256 A CN 101700256A CN 200910079700 A CN200910079700 A CN 200910079700A CN 200910079700 A CN200910079700 A CN 200910079700A CN 101700256 A CN101700256 A CN 101700256A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- chromium
- zinc
- selenium
- blood fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 29
- 210000004369 blood Anatomy 0.000 title claims abstract description 29
- 230000001603 reducing effect Effects 0.000 title claims abstract description 22
- 239000002131 composite material Substances 0.000 title abstract description 4
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 63
- 239000011720 vitamin B Substances 0.000 claims abstract description 63
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 50
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 50
- 239000011651 chromium Substances 0.000 claims abstract description 39
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 36
- 239000011701 zinc Substances 0.000 claims abstract description 28
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 28
- 239000011669 selenium Substances 0.000 claims abstract description 27
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 26
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 25
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229940046009 vitamin E Drugs 0.000 claims abstract description 25
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 25
- 239000011709 vitamin E Substances 0.000 claims abstract description 25
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000011733 molybdenum Substances 0.000 claims abstract description 23
- 229910052750 molybdenum Inorganic materials 0.000 claims abstract description 23
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229930003270 Vitamin B Natural products 0.000 claims description 62
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 40
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 39
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 34
- 241000229143 Hippophae Species 0.000 claims description 33
- 235000003935 Hippophae Nutrition 0.000 claims description 31
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 20
- 229940055726 pantothenic acid Drugs 0.000 claims description 20
- 235000019161 pantothenic acid Nutrition 0.000 claims description 20
- 239000011713 pantothenic acid Substances 0.000 claims description 20
- 229960002685 biotin Drugs 0.000 claims description 19
- 235000020958 biotin Nutrition 0.000 claims description 19
- 239000011616 biotin Substances 0.000 claims description 19
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 17
- 229960000304 folic acid Drugs 0.000 claims description 17
- 235000019152 folic acid Nutrition 0.000 claims description 17
- 239000011724 folic acid Substances 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 6
- 239000011573 trace mineral Substances 0.000 abstract description 31
- 235000013619 trace mineral Nutrition 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 23
- 235000003145 Hippophae rhamnoides Nutrition 0.000 abstract description 4
- 240000000950 Hippophae rhamnoides Species 0.000 abstract description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 2
- 229940046001 vitamin b complex Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 22
- 229940091258 selenium supplement Drugs 0.000 description 20
- 239000003925 fat Substances 0.000 description 19
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 17
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 11
- -1 nicotiamide Chemical compound 0.000 description 11
- 239000002775 capsule Substances 0.000 description 10
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000654 additive Substances 0.000 description 9
- 229940087168 alpha tocopherol Drugs 0.000 description 9
- 229940107218 chromium Drugs 0.000 description 9
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 9
- 229960000984 tocofersolan Drugs 0.000 description 9
- 239000002076 α-tocopherol Substances 0.000 description 9
- 235000004835 α-tocopherol Nutrition 0.000 description 9
- 230000000996 additive effect Effects 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 7
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 239000011655 sodium selenate Substances 0.000 description 7
- 235000018716 sodium selenate Nutrition 0.000 description 7
- 229960001881 sodium selenate Drugs 0.000 description 7
- 239000011576 zinc lactate Substances 0.000 description 7
- 235000000193 zinc lactate Nutrition 0.000 description 7
- 229940050168 zinc lactate Drugs 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 229910000323 aluminium silicate Inorganic materials 0.000 description 6
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 229910052749 magnesium Inorganic materials 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011684 sodium molybdate Substances 0.000 description 5
- 235000015393 sodium molybdate Nutrition 0.000 description 5
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 229940089653 folic acid 0.3 mg Drugs 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HPCCGRCEBFBZQP-UHFFFAOYSA-N chromium;pyridine-3-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CN=C1 HPCCGRCEBFBZQP-UHFFFAOYSA-N 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000745 gonadal hormone Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 102000003670 Carboxypeptidase B Human genes 0.000 description 1
- 108090000087 Carboxypeptidase B Proteins 0.000 description 1
- 229910021556 Chromium(III) chloride Inorganic materials 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- JJWSNOOGIUMOEE-UHFFFAOYSA-N Monomethylmercury Chemical compound [Hg]C JJWSNOOGIUMOEE-UHFFFAOYSA-N 0.000 description 1
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical compound C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- XSCQURIRMINZIY-UHFFFAOYSA-N [Se].COC(C1=CC=CC=C1)OC#N Chemical compound [Se].COC(C1=CC=CC=C1)OC#N XSCQURIRMINZIY-UHFFFAOYSA-N 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000170 anti-cariogenic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 239000011805 ball Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960000359 chromic chloride Drugs 0.000 description 1
- 229940046374 chromium picolinate Drugs 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 description 1
- 150000004777 chromones Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- UBFWAFZODRGFIF-UHFFFAOYSA-N cyanic acid;selenium Chemical compound [Se].OC#N UBFWAFZODRGFIF-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 208000036654 deficiency anemia Diseases 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940063755 folic acid 0.1 mg Drugs 0.000 description 1
- 229940106305 folic acid 20 mg Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229960000314 zinc acetate Drugs 0.000 description 1
- 235000013904 zinc acetate Nutrition 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 229940043825 zinc carbonate Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 229940110280 zinc methionine Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- CNMFGFBWPBBGKX-SCGRZTRASA-L zinc;(2s)-2-amino-4-methylsulfanylbutanoate Chemical compound [Zn+2].CSCC[C@H](N)C([O-])=O.CSCC[C@H](N)C([O-])=O CNMFGFBWPBBGKX-SCGRZTRASA-L 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
一种用于降低血脂的药物组合物,该组合物包括沙棘、复合维生素B、维生素E及微量元素锌、硒、铬、钼,用于高血脂人群,在降低血脂方面很有效,可长期施用或按疗程施用。
Description
技术领域:本发明涉及医药保健品技术领域;尤其是用于降低血脂的药物组合物。
背景技术:该组合物包括沙棘、复合维生素B、维生素E及微量元素锌、硒、铬、钼。
沙棘是一种既是食品又是药品的天然中药材,有健脾消食,祛痰止咳,活血祛瘀之功效;临床用于治疗脾虚食少,咳嗽痰多,血瘀经闭,跌打瘀肿等病症;现代药理研究证实沙棘具有:1、降血脂作用;2、保肝作用;3、抗肿瘤作用;4、抗氧化,抗衰老作用;5、对造血细胞有促进作用;6、降低血黏度、抗凝血、抗血栓作用;7、增强免疫功能;8、抗心肌缺血、缺氧、保护心肌功能;9.抗溃疡作用;10、抗炎疗伤作用;11、抗过敏作用;12、抗放射作用;13、强体抗疲劳作用;能使动物唾液、胃肠腺体分泌增加,胃蛋白酶含量升高,同时对胃肠运动功能有刺激作用,能使胃肠节律性收缩周期延长,振幅增大等影响胃肠道的功能;15、此外还能抗心律失常,预防和对抗庆大霉素所致的耳毒反应。
B族维生素参与机体内蛋白质、脂肪和糖代谢,使脑细胞的兴奋和抑制处于平衡状态,它包括维生素B1、维生素B2、烟酰胺、泛酸、生物素、维生素B6、维生素B12、叶酸等,在体内协同发挥生理作用。维生素B1参与体内蛋白质、脂肪、碳水化合物的分解代谢和合成代谢,缺乏时可致以脚气病为代表的各种代谢障碍,此外维生素B1还参与神经冲动反应,维持心肌正常功能,维持正常食欲,胃肠蠕动和消化液分泌等;维生素B2又名核黄素,是机体中许多重要辅酶的组成部分,参与体内的物质代谢,保证体内氧化还原反应和能量生成,参与体内抗氧化防御系统,缺乏时主要表现口腔生殖系统综合症、生长障碍、缺铁性贫血、湿性皮炎、减少红细胞生成、影响神经系统功能、降低视力等;烟酰胺又称尼克酰胺或维生素PP,其生理功能是参与体内新陈代谢,维持正常神经系统功能,保证性激素等的合成,缺乏时可发生癞皮病,主要表现为皮炎、腹泻、痴呆三大症状;泛酸在每一生物体内广泛存在,参与广泛的代谢活动,已知有70多种酶在催化机体各类生物化学反应中都需要泛酸参与,否则便会代谢失调;生物素也是一种B族维生素,与其它B族维生素协调参与人体物质和能量代谢,它与核酸的合成,性激素的合成关系密切,它还具有防治白发、秃头的功效;维生素B6在体内起转氨酶、氨基酸脱羧酶的辅酶作用,保证氨基酸、糖原、脂肪酸及一碳单位、烟酸等物质的新陈代谢,保证核酸和蛋白质的合成与细胞的正常增殖,保证与一羟色胺、牛磺酸、多巴胺等神经递质的正常代谢,保证正常的免疫功能,缺乏时免疫力下降,还可造成神经系统的损害;维生素B12参与体内核酸,胆碱,氨基酸的合成及脂肪与糖的代谢,对骨髓造血功能,消化道上皮细胞功能,肝脏功能和神经系统髓鞘功能的完整有一定作用,它是发挥正常智力所必须的维生素,如果缺乏不仅造成智力障碍,还会出现营养性贫血,影响对脑中血液供给;叶酸参与氨基酸和核酸的合成,并与维生素B12共同促进细胞的生成与成熟,缺乏时正常细胞不能进行有丝分裂,会出现神经病学的症状,如:记忆丧失,抑郁症及痴呆症等;
维生素E是所有具有α-生育酚生物活性的色酮衍生物的统称,其中α-生育酚的活性最高,具有抗氧化,避免生物膜发生脂质过氧化反应的作用;阻止低密度脂蛋白氧化形成的作用,从而防止动脉粥样硬化和心血管疾病的发生;此外还有调节免疫、延缓衰老、抑制肿瘤、促进胚胎发育和生殖能力及对神经和骨骼的保护作用等。
微量元素锌被融合在生物大分子配位体——蛋白质、核酸、膜(主要为膜蛋白)中,生成稳定的含金属的生物大分子络合物——金属蛋白、金属核酸络合物等,目前,已知这些物质参与碳水化合物、脂类、蛋白质及核酸的合成和降解过程,在六大类酶中都有含锌酶的存在;锌也是增强免疫活力的主要元素;锌能通过激活羧肽酶B促进胰岛素原转化为胰岛素,缺锌使胰岛素在外周组织的活性受阻,致糖耐量曲线异常。
微量元素硒有明显降低血清总胆固醇、甘油三酯和脂质过氧化物,提高高密度脂蛋白,加速体内多余脂肪代谢的作用;硒还具有强抗氧化功能,可预防心脏病;通过增强免疫识别系统清除癌细胞而抗癌;解除和排泄重金属离子,对汞、甲基汞、镉、铅等有解毒作用;缺硒可使人体胰岛素分泌减少,糖耐量减低,抗氧化能力下降而加速人体衰老和智力下降。
铬是胰岛素的“协同激素”,以具有活性的含铬有机化合物“葡萄糖耐受因子(GTF)”形式增强胰岛素的作用,主要是维持机体正常的糖代谢及脂代谢,不足时会出现以下症状:削弱葡萄糖耐量、加重高血糖症、尿糖、低血糖症、加速胰岛素循环、减少胰岛素受体数量、降低胰岛素结合能力、体重减轻、增加脂肪含量、增加视觉压力等。环境中稳定存在两种价态的铬,即三价铬和六价铬,三价铬具有生理活性,在适量的范围内施用有益无害,六价铬是一种强氧化剂,对人体具有毒副作用。
钼是人体必需微量元素之一,它是多种酶的构成元素,能帮助碳水化合物和脂肪的代谢,它参与解除人体内有毒醛类的毒害,消除人体自由基,具有抗癌、抗衰老,增强免疫力及防龋齿的功能;缺钼可诱发心血管疾病、癌症及龋齿。
应用含有沙棘、维生素B1、维生素B2、维生素B6、烟酰胺、泛酸、生物素、维生素B12、叶酸、维生素E及微量元素锌、硒、铬、钼作为有效组分的组合物已为人所知,但将沙棘、维生素B1、维生素B2、烟酰胺、泛酸、生物素、维生素B6、维生素B12、叶酸、维生素E和微量元素锌、硒、铬、钼配伍用于降低血脂的药物组合物尚未报道。
当前用于降低血脂的药品或保健品种类有多种,但是有毒副作用的药类很多,保健食品靶点少环节欠缺,需要完善,并且成本和售价都很高。
发明内容:为了克服现有降低血脂药物的缺点和不足,本发明的目的是提供一种组合物,该组合物通过沙棘增加维生素B1、维生素B2、维生素B6、烟酰胺、泛酸、生物素、维生素B12、叶酸、维生素E及微量元素锌、硒、铬、钼降低血脂之功效,同时通过微量元素锌、硒、铬、钼及维生素B1、维生素B2、烟酰胺、泛酸、生物素、维生素B6、维生素B12、叶酸、维生素E,补充和增强沙棘抑制血糖升高与血中胆固醇含量的效果,即使长期施用也没有任何副作用;由于广泛研究的结果,本发明人发现了沙棘、维生素B1、维生素B2、烟酰胺、泛酸、生物素、维生素B6、维生素B12、叶酸、维生素E与及微量元素锌、硒、铬、钼的新型组合,这一新型组合对于降低血脂有协同效果;而单用沙棘、复合维生素B、维生素E及微量元素锌、硒、铬、钼,其效果均不及本组合物;本组合物不存在配伍禁忌,无毒副作用,并且成本低,从而构成本发明。
本发明提供了用于降低血脂的药物组合物,它包括作为有效组分的沙棘、维生素B1、维生素B2、烟酰胺、泛酸、生物素、维生素B6、维生素B12、叶酸、维生素E及微量元素锌、硒、铬、钼。
沙棘为胡颓子科落叶灌木或小乔木沙棘(Hippophae rhamnoides)的干燥果实供用;有西藏沙棘、肋果沙棘、江孜沙棘、中亚沙棘、蒙古沙棘等品种;主产于内蒙古、山西、陕西、青海等地;本发明所用沙棘可用其提取物作为原料。
用于本发明的维生素B1(VitaminB1)、维生素B2(VitaminB2)、烟酰胺(Nicotinamide)、泛酸(Pantothenic Acid)、生物素(Vitamin H)、维生素B6(VitaminB6)、维生素B12(VitaminB12)、叶酸(Folic Acid),均是水溶性维生素,在体内没有蓄积;维生素E(Vitamin E)是脂溶性维生素,按本发明所用剂量有益无害;锌(Zn)、硒(Se)、铬(Cr)、钼(Mo)为人体必需微量元素;本发明中的微量元素锌可选用柠檬酸锌、醋酸锌、碳酸锌、氧化锌、氯化锌、乳酸锌、硫酸锌、葡萄糖酸锌、单蛋氨酸锌等,微量元素硒可选用硒蛋氨酸、甲氧基苄氰酸硒、次苯基双氰酸硒、硒化卡拉胶、半胱氨酸硒、硒化甲硫氨酸、亚硒酸钠、硒酸钠等,微量元素铬选用三价铬如:三氯化铬、烟酸铬、吡啶甲酸铬、铬酵母等,微量元素钼可选用钼酸铵、钼酸钠等,均有专业生产厂及供货商。
本发明的组合物主要适用于高血脂人群,按本发明,沙棘的有效用量以整体天然药材计为300-10000mg天,维生素B1的有效用量为0.5-20mg/天,维生素B2的有效用量为0.5-20mg/天,烟酰胺的有效用量为5-50mg/天,泛酸的有效用量为2-20mg/天,生物素的有效用量为0.01-0.1mg/天,维生素B6的有效用量为0.5-10mg/天,维生素B12的有效用量为0.001-0.025mg/天,叶酸的有效用量为0.1-1mg/天,维生素E的有效用量(以α-生育酚当量计)为5-150mgα-TE/天,微量元素锌的有效用量以元素锌计为5-20mg/天,硒的有效用量以元素硒计为0.015-0.1mg/天,铬的有效用量以元素铬计为0.015-0.15mg/天,钼的有效用量以元素钼计为0.02-0.06mg/天。
本发明的组合物可按下列药物制剂形式施药或直接服用,例如,口服制剂(如颗粒、粉末、胶囊、丸、片、干糖浆、液态制剂),或食物如固体食物(如饼干),是与其它已知的添加剂混合而制备的,这类添加剂例如:载体、崩解剂、缓释剂、赋形剂、填充剂、包覆剂、粘结剂、润滑剂、抗氧剂、涂覆剂、着色剂、矫味剂、甜味剂、蔗糖替代品、营养强化剂、香味剂、表面活性剂、增塑剂、PH调节剂、清新剂、悬浮剂、消泡剂、防腐剂、增稠剂、增溶助剂等,按通常的方法进行制备或者将它们作为功能性组分或添加剂加入食物。
按本发明,沙棘、维生素B1、维生素B2、烟酰胺、泛酸、生物素、维生素B6、维生素B12、叶酸、维生素E及微量元素锌、硒、铬、钼各组份可分别制剂,施用时可将各组份的制剂混合后使用或不同时混合而使用。
本发明的优点是本组合物从多环节协同发挥降低血脂的作用,对降低血脂有显著的效果,原料来源充足,成本低,组合物中各组分无毒副作用,无配伍禁忌。
附表1为本组合物与沙棘组份和维生素加元素组份对(STZ)致糖尿病模型大鼠降血脂试验效果比较。
下面将参考实施例及测试实施例效果比较列表来详细叙述本发明。
实施例1:
沙棘 1000mg,
维生素B1 3mg,
维生素B2 3mg,
维生素B6 2mg,
维生素B12 0.003mg,
叶酸 0.3mg,
乳酸锌(以微量元素锌计) 10mg,
硒酸钠(以微量元素硒计) 0.02mg,
烟酸铬(以微量元素铬计) 0.1mg,
维生素E(以α-生育酚当量计) 10mgα-TE。
将上述组分进一步与适当量的添加剂如硅铝酸镁、聚溶剂化物60和丙二醇均匀地混合,将所得混合物均匀地填入胶囊而得9颗胶囊,每日3次,每次3颗胶囊。
实施例2:
沙棘 2000mg,
维生素B1 3mg,
维生素B2 3mg,
维生素B6 2mg,
维生素B12 0.003mg,
叶酸 0.3mg,
烟酰胺 10mg,
乳酸锌(以微量元素锌计) 8mg,
硒酸钠(以微量元素硒计) 0.02mg,
铬酵母(以微量元素铬计) 0.02mg,
维生素E(以α-生育酚当量计) 10mgα-TE。
将上述组分进一步与适当量的添加剂如硅铝酸镁、聚溶剂化物60和丙二醇均匀地混合,将所得混合物均匀地填入胶囊而得9颗胶囊,每日3次,每次3颗胶囊。
实施例3:
沙棘 3000mg,
维生素B1 3mg,
维生素B2 3mg,
维生素B6 2mg,
维生素B12 0.003mg,
叶酸 0.3mg,
烟酰胺 10mg,
乳酸锌(以微量元素锌计) 10mg,
硒酸钠(以微量元素硒计) 0.02mg,
铬酵母(以微量元素铬计) 0.02mg,
钼酸钠(以微量元素钼计) 0.03mg,
维生素E(以α-生育酚当量计) 10mgα-TE。
将上述组分进一步与适当量的添加剂如硅铝酸镁、聚溶剂化物60和丙二醇均匀地混合,将所得混合物均匀地填入胶囊而得9颗胶囊,每日3次,每次3颗胶囊。
实施例4:
沙棘 5500mg,
维生素B1 3mg,
维生素B2 3mg,
维生素B6 2mg,
维生素B12 0.003mg,
叶酸 0.3mg,
烟酰胺 10mg,
生物素 0.01-0.1mg,
乳酸锌(以微量元素锌计) 10mg,
硒酸钠(以微量元素硒计) 0.02mg,
铬酵母(以微量元素铬计) 0.02mg,
钼酸钠(以微量元素钼计) 0.03mg,
维生素E(以α-生育酚当量计) 10mgα-TE。
将上述组份进一步与适当量的添加剂如甘露糖醇、羟丙基纤维素、硅铝酸镁和调味剂均匀地混合,再将所得混合物制成3包粒状物;每日服3次,每次服一包。
实施例5:
沙棘 300mg,
维生素B1 0.5mg,
维生素B2 0.5mg,
维生素B6 0.5mg,
维生素B12 0.001mg,
叶酸 0.1mg,
烟酰胺 5mg,
泛酸 2mg,
生物素 0.01mg,
乳酸锌(以微量元素锌计) 5mg,
硒酸钠(以微量元素硒计) 0.015mg,
铬酵母(以微量元素铬计) 0.015mg,
钼酸钠(以微量元素钼计) 0.02mg,
维生素E(以α-生育酚当量计) 5mgα-TE。
将上述组份进一步与适当量的添加剂如甘露糖醇、羟丙基纤维素、硅铝酸镁和调味剂均匀地混合,再将所得混合物制成3包粒状物;每日服3次,每次服一包。
实施例6:
沙棘 10000mg,
维生素B1 1mg,
维生素B2 10mg,
维生素B6 0.025mg,
维生素B12 20mg,
叶酸 20mg,
烟酰胺 50mg,
泛酸 20mg,
生物素 0.1mg,
乳酸锌(以微量元素锌计) 20mg,
硒酸钠(以微量元素硒计) 0.1mg,
铬酵母(以微量元素铬计) 0.15mg,
钼酸钠(以微量元素钼计) 0.06mg,
维生素E(以α-生育酚当量计) 150mgα-TE。
将上述组份进一步与适当量的添加剂如甘露糖醇、羟丙基纤维素、硅铝酸镁和调味剂均匀地混合,再将所得混合物制成3包粒状物;每日服3次,每次服一包,连服10日,停服5日,再服10日。
经动物试验证实本组合物属无毒级;人群服用也未见毒副反应。
实施例7:
选SD系雄性大鼠48只进食高脂饲料,饲养4周后按25mg/kg体重一次腹腔内注射STZ(链尿佐菌素),于2周后禁食8小时后,按2g/kg体重灌服20%D-葡萄糖溶液,做口服糖耐量试验,凡0和2小时血糖分别大于7.0和11.0mmol/L的大鼠,作为糖尿病造模成功大鼠,将造模成功大鼠随机分为4组,每组12只,分别为A组,B组,C组,D组,试验各组每天经口给予被检物和等量的蒸馏水混悬液灌胃一次,对照组每天给予等量生理盐水灌胃一次,于给药12周后第3日禁食10小时,颈动脉采血,分别测定总胆固醇,甘油三脂,高密度脂蛋白,三项指标。
相关数据见附表1。
附表1:本组合物与沙棘组份和维生素加元素组份对(STZ)致糖尿病模型大鼠降血脂试验效果比较:
从表1中可明显看出,服用本组合物制剂与服用沙棘组份及维生素加元素组份对比高血脂模型大鼠降血脂试验效果有非常显著的差异。
Claims (5)
1.一种用于降低血脂的药物组合物,其特征是,它由下列原料按重量配比制成:
沙棘 300-10000mg,
维生素B1 0.5-20mg,
维生素B2 0.5-20mg,
维生素B6 0.5-10mg,
维生素B12 0.001-0.025mg,
叶酸 0.1-1mg,
烟酰胺 0-50mg,
泛酸 0-20mg,
生物素 0-0.1mg,
锌 5-20mg,
硒 0.015-0.1mg,
铬 0.015-0.15mg,
钼 0-0.06mg,
维生素E 5-150mg a-TE。
2.根据权利要求1所述的用于降低血脂的药物组合物,其特征是,它由下列原料按重量配比制成:
沙棘 300-10000mg,
维生素B1 0.5-20mg,
维生素B2 0.5-20mg,
维生素B6 0.5-10mg,
维生素B12 0.001-0.025mg,
叶酸 0.1-1mg,
烟酰胺 5-50mg,
泛酸 0-20mg,
生物素 0-0.1mg,
锌 5-20mg,
硒 0.015-0.1mg,
铬 0.015-0.15mg,
钼 0-0.06mg,
维生素E 5-150mg a-TE。
3.根据权利要求1所述的用于降低血脂的药物组合物,其特征是,它由下列原料按重量配比制成:
沙棘 300-10000mg,
维生素B1 0.5-20mg,
维生素B2 0.5-20mg,
维生素B6 0.5-10mg,
维生素B12 0.001-0.025mg,
叶酸 0.1-1mg,
烟酰胺 5-50mg,
泛酸 0-20mg,
生物素 0-0.1mg,
锌 5-20mg,
硒 0.015-0.1mg,
铬 0.015-0.15mg,
钼 0.02-0.06mg,
维生素E 5-150mg a-TE。
4.根据权利要求1所述的用于降低血脂的药物组合物,其特征是,它由下列原料按重量配比制成:
沙棘 300-10000mg,
维生素B1 0.5-20mg,
维生素B2 0.5-20mg,
维生素B6 0.5-10mg,
维生素B12 0.001-0.025mg,
叶酸 0.1-1mg,
烟酰胺 5-50mg,
泛酸 0-20mg,
生物素 0.01-0.1mg,
锌 5-20mg,
硒 0.015-0.1mg,
铬 0.015-0.15mg,
钼 0.02-0.06mg,
维生素E 5-150mg a-TE。
5.根据权利要求1所述的用于降低血脂的药物组合物,其特征是,它由下列原料按重量配比制成:
沙棘 300-10000mg,
维生素B1 0.5-20mg,
维生素B2 0.5-20mg,
维生素B6 0.5-10mg,
维生素B12 0.001-0.025mg,
叶酸 0.1-1mg,
烟酰胺 5-50mg,
泛酸 2-20mg,
生物素 0.01-0.1mg,
锌 5-20mg,
硒 0.015-0.1mg,
铬 0.015-0.15mg,
钼 0.02-0.06mg,
维生素E 5-150mg a-TE。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910079700A CN101700256A (zh) | 2009-03-17 | 2009-03-17 | 用于降低血脂的药物组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910079700A CN101700256A (zh) | 2009-03-17 | 2009-03-17 | 用于降低血脂的药物组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101700256A true CN101700256A (zh) | 2010-05-05 |
Family
ID=42155199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910079700A Pending CN101700256A (zh) | 2009-03-17 | 2009-03-17 | 用于降低血脂的药物组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101700256A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106376936A (zh) * | 2016-08-31 | 2017-02-08 | 成都润馨堂药业有限公司 | 一种具有降脂功能的保健食品配方及制备方法 |
-
2009
- 2009-03-17 CN CN200910079700A patent/CN101700256A/zh active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106376936A (zh) * | 2016-08-31 | 2017-02-08 | 成都润馨堂药业有限公司 | 一种具有降脂功能的保健食品配方及制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101700256A (zh) | 用于降低血脂的药物组合物 | |
| CN101584709A (zh) | 用于降低血糖与血脂和治疗糖尿病的药物组合物 | |
| CN101574370A (zh) | 用于降低血糖和血脂的药物组合物 | |
| CN101574371A (zh) | 用于降低血糖和血脂的药物组合物 | |
| CN101579371A (zh) | 用于降低血脂的药物组合物 | |
| CN101569649A (zh) | 用于降低血糖的药物组合物 | |
| CN101569636A (zh) | 用于降低血脂的药物组合物 | |
| CN101474334A (zh) | 用于降低血糖的药物组合物 | |
| CN101584710A (zh) | 用于降低血糖与血脂和治疗糖尿病的药物组合物 | |
| CN101596287A (zh) | 用于降低血糖和血脂的药物组合物 | |
| CN101574435A (zh) | 用于降低血糖的药物组合物 | |
| CN101474201A (zh) | 用于降低血脂的药物组合物 | |
| CN101574406A (zh) | 用于降低血脂的药物组合物 | |
| CN101574401A (zh) | 用于降低血脂的药物组合物 | |
| CN101579398A (zh) | 用于降低血糖与血脂和治疗糖尿病的药物组合物 | |
| CN101579374A (zh) | 用于降低血脂的药物组合物 | |
| CN101569646A (zh) | 用于降低血糖的药物组合物 | |
| CN101632699A (zh) | 用于降低血脂的药物组合物 | |
| CN101590116A (zh) | 用于降低血脂的药物组合物 | |
| CN101632700A (zh) | 用于降低血脂的药物组合物 | |
| CN101596213A (zh) | 用于降低血糖和血脂的药物组合物 | |
| CN101574367A (zh) | 用于降低血糖和血脂的药物组合物 | |
| CN101574366A (zh) | 用于降低血糖和血脂的药物组合物 | |
| CN101669976A (zh) | 用于降低血脂的药物组合物 | |
| CN101579447A (zh) | 用于降低血糖和血脂的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100505 |